Genetic experiments established that p63 is crucial for the development and maintenance of pluri-stratified epithelia and KLF4 for the barrier function of the skin. KLF4 is one of the factors that reprogram differentiated cells to iPS. We investigated the relationship between p63 and KLF4 using RNA interference, overexpression, chromatin immunoprecipitation and transient transfections with reporter constructs. We find that p63 directly represses KLF4 in normal keratinocytes (KCs) by binding to upstream promoter sites. Unlike p63, KLF4 levels are high in the upper layers of human skin and increase upon differentiation of KCs in vitro. In HaCaT KCs, which harbor two mutant alleles of p53, inactivation of p63 and of mutant p53 leads to KLF4 repression. p63 and p53 mutants are bound to sites in the KLF4 core promoter. Importantly, expression of the H179Y and R282Q p53 mutants in primary KCs is sufficient to activate endogenous KLF4. Finally, immunohistochemical analysis of tissue arrays confirms increased coexpression of KLF4 and mutant p53 in squamous cell carcinomas. Our data indicate that suppression of KLF4 is part of the growth-promoting strategy of p63 in the lower layers of normal epidermis, and that tumor-predisposing p53 mutations hijack p63 to a different location on the promoter, turning it into an activator of this reprogramming factor.
Introduction p63 belongs to the p53 and p73 family of transcription factors (TFs) that share a conserved DNA-binding domain and similar DNA target sequences in promoters and enhancers of eukaryotic genes. Genetic and biochemical work clarified that p53 directs the DNAdamage response by impinging on cell-cycle control and pro-apoptotic pathways (Aylon and Oren, 2007; Riley et al., 2008) . p63, on the other hand, is involved in the development and maintenance of pluri-stratified epithelia, including skin (Koster and Roop, 2004; McKeon, 2004) . Several p63 proteins have been described, resulting from two distinct promoters, TAp63 and DNp63, and from alternative mRNA splicing at the 3 0 end of the gene. The major isoform present in the skin, DNp63a, is essential for the development of ectoderm and stratification. Several human syndromes showing abnormalities in limbs, skin and epithelial annexes are caused by missense mutations in the p63 gene (Rinne et al., 2006) . p63 is crucial for the activation of the epithelial-cell adhesion program (Carroll et al., 2006; Barbieri et al., 2006; reviewed in Carroll et al., 2007) and it has a major role in maintaining the proliferative potential of stem cells (Senoo et al., 2007; Su et al., 2009) . Mice lacking p63 die soon after birth with severe defects in limb and craniofacial development and absence of skin (Mills et al., 1999; Yang et al., 1999) . Unlike p53, p63 is not mutated; yet it is overexpressed in many epithelial tumors, notably squamous cell carcinomas (SCCs) (Deyoung and Ellisen, 2007) .
Another TF of which ablation leads to severe skin defects is KLF4: KO mice die 24 h post-birth because of lack of barrier function and consequent liquid loss (Segre et al., 1999) . Mice have impaired late differentiation of outer skin layers and perturbed cornified envelop formation. In contrast, overexpression of KLF4 in the skin accelerates the formation of the epidermal barrier (Jaubert et al., 2003) . The role extends to other multilayered epithelia, as conditional deletion in the cornea leads to epithelial fragility (Swamynathan et al., 2007) . KLF4 belongs to a large family of Kruppel-like activators with zinc-finger DNA-binding domains, recognizing the common GC boxes found in many, if not most, promoters (Kaczynski et al., 2003) . Unlike other members of the family, expression is confined to specific tissues, such as the gut, skin and thymic epithelia (Garrett-Sinha et al., 1996; Shields et al., 1996; Conkright et al., 1999) .
In general, KLF4 is usually present in well-differentiated, non-proliferating cells, where it serves the role of growth suppressor and is activated strongly in fibroblasts arrested by serum withdrawal (reviewed in Ghaleb et al., 2005) . Profiling experiments have shown that KLF4 activates genes that inhibit proliferation, and represses genes that promote it Whitney et al., 2006; Swamynathan et al., 2008) . However, studies on KLF4 in tumors suggest that its role is extremely complex and variegated. In the intestine, genetic and expression profiling data indicate that it indeed functions as a tumor suppressor, often inactivated by epigenetic mechanisms in carcinomas (reviewed by Wei et al., 2006) . On the other hand, KLF4 has emerged in profiling experiments as a gene overexpressed in breast and skin cancers, and overexpression in immortalized rat kidney cells results in hyperplasia and dysplasia (Foster et al., 1999 (Foster et al., , 2000 Huang et al., 2005; Chen et al., 2008) . Transgenic mice in which KLF4 was expressed in the basal layer of the epidermis showed hyperplasia/dysplasia and, in the context of a p53 hemizygous background, these mice developed subcutaneous sarcomas . Moreover, KLF4 overrides Ras V12 -induced senescence and induces transformation in primary fibroblasts (Rowland et al., 2005) .
Links between p53 and KLF4 surfaced in many studies. Cell-cycle block by DNA-damaging agents activates KLF4 expression, but apoptotic doses decrease it (Yoon et al., 2003) . Interestingly, maintaining elevated levels of KLF4 prevents apoptosis mediated by p53 (Ghaleb et al., 2007) , and elimination of KLF4 induction leads to apoptosis in cells treated with nonapoptotic doses of DNA-damaging agents (Zhou et al., 2009) . KLF4 activates CDKIs, p21, p27 and p57 (Chen et al., 2001 Wei et al., 2006; Swamynathan et al., 2008) ; in particular, it cooperates with p53 in activating p21 (Zhang et al., 2000) . KLF4 represses p53 transcription by binding to GC boxes in the p53 promoter: under these conditions, the levels of p21 and Cyclin D1 are crucial for deciding as to whether KLF4 exerts a tumor suppressive-high p21 or oncogenic-high Cyclin D1 activity (Rowland et al., 2005) .
In addition to mediating a G1/S block, KLF4 prevents cells to enter mitosis with damaged DNA (Yoon et al., 2005) , and indeed it binds to and represses the Cyclin B2 promoter directly (Yoon and Yang, 2004) . Finally, and most importantly, in combination with OCT4, SOX2 and Nanog, KLF4 reprograms a wide range of differentiated cells into iPS, a state resembling very closely, if not identical to, totipotent embryonic stem cells (Takahashi and Yamanaka, 2006) . Thus, overexpression of this TF has profound and lasting consequences on the expression of growth-promoting genes. This process is influenced by the p53 status Kawamura et al., 2009; Mario´n et al., 2009; Utikal et al., 2009) .
Our lab has been involved in the identification of p63 targets in human KCs, either by expression profiling or by ChIP (chromatin immunoprecipitation) on chip analysis (Vigano`et al., 2006; Testoni et al., 2006) . In this report, we investigated the possible regulation between p63 and KLF4 in primary and immortalized human KCs harboring mutant alleles of p53.
Results

KLF4 is a transcriptional target of p63
We inactivated p63 with a specific siRNA capable of recognizing all p63 transcripts and analyzed KLF4 expression, at both the mRNA and protein levels. As shown in Figure 1 , efficient downregulation of DNp63a, the most abundant isoform expressed in KCs, leads to KLF4 protein increase both in neonatal (nKCs) and in adult (aKCs) keratinocytes; mRNA levels are significantly higher only in nKCs (Figures 1a and b) . The different behavior of nKCs versus aKCs is likely due to the different origin of the cells and their differentiation state; in fact, the basal levels of KLF4 are higher in aKCs ( Figure 1c ). As controls, we assayed the p63 targets p21 (CDKN1A) and KLF5: the former was decreased, as expected, whereas the latter was increased in nKCs.
We performed an in silico analysis of the KLF4 promoter region and located putative p53/p63 and KLF4 binding sites, which are conserved in other mammalian species (Figure 1d ). We then performed ChIP with p53, p63 and KLF4 antibodies in aKCs; Figure 1e shows that regions D (À2225), E (À1784) and I ( þ 467) are bound by p63 and KLF4 in vivo, whereas areas containing other potential sites are not. p53 is not bound to any of the analyzed regions. The C40 region on the p63 locus served as a positive control for p63 binding (Pozzi et al., 2009) . Additional ChIP results are given in Supplementary 1. Taken together, these results show that p63 directly represses KLF4 transcription in primary KCs by binding to discrete upstream sequences in the promoter.
KLF4 is regulated during differentiation of the skin
We analyzed the expression of KLF4 in nKCs induced to differentiate in vitro by addition of CaCl 2 to the medium. Figure 2a shows that KLF4 increases already after 3 days, as detected by western blot, and further increases at later time points. In parallel, DNp63a is progressively reduced, as expected. The KLF4 mRNA is also upregulated, moderately at early time points and showing the highest levels after 10 days, as revealed by quantitative reverse transcriptase-PCR (qRT-PCR) analysis (Figure 2b ). KLF5, also a putative p63 target (NC and RM, unpublished) , is upregulated during this process (Figure 2b ). KC differentiation was monitored by measuring mRNA levels of Involucrin and p21, which were reported to increase (Figure 2a , right panels), while DNp63a and two previously identified targets activated by p63, SMAD7 and SMURF2, significantly decreased (Pozzi et al., 2009) . We also monitored KLF4 expression by immunofluorescence staining with p63 and KLF4 antibodies. These experiments confirmed the increase of KLF4 expression, concomitant to a decrease of p63 (Figure 2c , left panels). Furthermore, while in undifferentiated KCs KLF4 is expressed at low levels only in the nuclei, at 5 days it appears also in the cytoplasm, and at 10 days it is distributed almost equally in the nucleus and the cytoplasm. Immunostaining with the KRT1 marker provides the control for differentiation (Figure 2c , right panels).
We analyzed KLF4 expression in human normal adult skin by confocal immunostaining. Supplementary 2 shows that KLF4 expression is mostly nuclear, lower in the basal layer and higher in the subcorneum, contrary to p63, where KLF4 is absent in the upper layers. Interestingly, costaining with p63 reveals that some cells in the basal and suprabasal layers coexpress the two proteins (indicated by the white arrows in the merge panel). The KLF4 data are similar to those reported for mouse epidermis (Segre et al., 1999; Jaubert et al., 2003; Foster et al., 2005) . Therefore, KLF4 is activated during keratinocyte differentiation in vitro and is mostly present in cells with low or non-existent levels of p63 in human skin.
KLF4 is differentially regulated in HaCaT cells
We decided to validate the results obtained above in HaCaT cells, an immortalized but not transformed KC cell line, by inactivating p63 by siRNA: the high KLF4 levels were downregulated at both protein and mRNA levels ( Figure 3a ). In contrast, overexpression of DNp63a caused a further increase in KLF4 protein and mRNA levels ( Figure 3b ). To ascertain whether this was a transcriptional effect, a luciferase reporter driven by the KLF4 promoter (Dang et al., 2002) was transfected in HaCaT cells together with scramble or p63 siRNAs: the activity was reduced upon inactivation of p63 (Figure 3c , left panel). On the other hand, the opposite was observed when the same construct was cotransfected with a DNp63a vector (Figure 3c , right panel), indeed indicating a transcriptional regulation of p63 on the KLF4 promoter. Finally, ChIP experiments in HaCaT cells confirmed direct in vivo binding of p53, p63 and KLF4 to the KLF4 promoter: note, however, that p63 binding was mostly mapped to regions B (À3385), G (À400) and I ( þ 467), which is different from that observed for primary KCs (compare Figures 1e and 3d) .
Furthermore, we detected the presence of p53, together with p63, on region G (À400), which contains p53/p63 motifs but is not bound in vivo by p53/p63 in primary KCs.
HaCaT cells harbor two mutant p53 alleles, carrying a histine to tyrosine mutation at position 179, and an arginine to tryptophan mutation at position 282 (Datto et al., 1995) . Both mutations are within the DNAbinding domain of p53 and typical of skin tumors (Pfeifer and Besaratinia, 2009) . Unlike p53 in normal KCs, of which levels are very low, mutant p53 is expressed at high levels, as in HaCaT cells, and retains the ability to functionally interact with the DNA (Stambolsky et al., 2010) .
We reasoned that the opposite regulation observed in HaCaT could be due to the presence of the p53 mutants, specifically impinging on p63-mediated regulation of KLF4 through the G (À400) region. We therefore inactivated p53 in HaCaT by transfecting siRNA: Figure 4a shows a reduction of the endogenous mutant p53; the levels of KLF4, and p53 mRNA, as measured by qRT-PCR, were substantially reduced. Importantly, the p63 mRNA and protein levels remained substantially high, indicating that the reduction of KLF4 was not secondary to an effect on p63 levels.
To further prove that p53 mutants are involved in KLF4 control, we overexpressed p53 H179Y and p53 R282Q, either alone or in combination, in neonatal and adult primary KCs, and analyzed KLF4 expression. As shown in Figure 4b , both mRNA and protein levels are increased after transient transfection of the p53 mutants; specifically, their combination yielded very strong overexpression of KLF4 in aKCs. and KLF4 expression during KC differentiation. DAPI staining is included to identify nuclei. In the right panels, the KRT1 marker of differentiation was used in double staining with p63 to monitor the differentiation process. Scale bars (20 mm) are depicted in white.
Activation of KLF4 by mutant p53 N Cordani et al It was previously shown that mutant p53 has a higher affinity for p63, and heteromeric complexes can be detected, notably in HaCaT cells (Gaiddon et al., 2001) . Therefore, to demonstrate that mutant p53 and p63 interact at specific sites on the KLF4 promoter, we performed ChIP and re-ChIP experiments with antibodies against p53 and p63. Although endogenous p53 mutants and p63 are similarly enriched on the same KLF4 promoter region G (À400) when considered separately (ChIP and re-ChIP with the same antibody), only ChIP with the p53 antibody followed by re-ChIP with that for p63 is able to enrich for the two TFs (Figure 4c, bottom panel) .
Altogether, these experiments indicate that p53 mutants have a direct positive effect on KLF4 expression, together with p63, by binding to a core promoter region of KLF4.
KLF4, p63 and p53 in skin tumors
The majority of SCCs of the skin have missense mutations in the TP53 gene, resulting in increased levels of p53 proteins (Pfeifer and Besaratinia, 2009 
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N Cordani et al not overly increased. Out of 20 SCCs, 15 showed overexpression rated 3, where 0 is no expression and 3 is maximum positivity of KLF4: in some cases, KLF4 showed nuclear staining, whereas in others expression was mostly in the cytoplasm; this finding has been reported before . As for p53, 8/20 SCCs had staining at level 3 and 4/20 at level 2: the figure of 60% of SCCs overexpressing p53 is confirmatory of previous studies. Note that constitutive overexpression of normal p53 in such tumors has not been reported, although overexpression is invariably associated with p53 mutations. In all but two cases-SCC9 and SCC10-whenever p53 levels were high, KLF4 levels were also high. In SCC17, the levels of KLF4 were unusually low, and p53 was indeed undetectable. Finally, there was no association of expression between p53 and KLF4 in other skin tumors. Figure 5 shows the immunohistochemical staining of representative SCC cases and comparison with normal skin. In none of the normal skin samples did we notice p53 signals above the background. In conclusion, these data support the notion that an overexpressed, mutated p53 is involved in the positive regulation of KLF4 in human SCC.
Discussion
In this report, we present evidence that KLF4 is negatively controlled by p63 in normal skin in the presence of physiological levels of wild-type p53, and that this regulation is subverted by oncogenic mutations of p53, establishing a direct link between these TFs, commonly overexpressed in SCCs. Because KLF4 overexpression cooperates in reprogramming differentiated cells, our findings have potential consequences for the mechanisms of formation of skin carcinomas.
p63 and KLF4 in normal skin
Genetic evidence clarified that p63 and KLF4 are TFs that have a crucial role in the epidermis (reviewed by Dai and Segre, 2004) . Expression data in mouse and humans have clearly shown that p63 and KLF4 mark two different territories in the skin: the first exclusively-in mice-or mostly-in humans-confined to the basal layer, whereas KLF4 is high in the granular and subcorneum strata. Our data showing that KLF4 expression is increased upon in vitro differentiation-as p63 decreases-and that p63 represses KLF4 transcription are in line with the expression data; this effect is more pronounced in adult KCs compared with neonatal, and it is directly exerted by binding to upstream and downstream sites in the KLF4 promoter region. In general, the analysis of p63 targets derived either by expression profiling or by location analysis (reviewed by Perez and Pietenpol, 2007; Vigano`and Mantovani, 2007) has lent support to the idea that the TF is important in determining the proliferative potential of skin basal KCs (Senoo et al., 2007; Su et al., 2009) : among activated targets, in particular, there are progrowth genes, whereas TFs involved in differentiation, such as c-Jun, C/EBPd and HBP1, are repressed. Pathways at the crossroad of these decisions, such as Notch, Wnt and SHH, are also controlled. KLF4, therefore, joins an increasingly long list of regulators that are kept at bay in the lower skin layers by p63's direct negative control. Transcriptional profiling has been performed by overexpressing KLF4 in the colon cancer cell line RKO and in an elegant system of corneal cells derived from KLF4-conditional null mice (Swamynathan et al., 2008) : this latter study, in particular, reported notorious targets of p63, such as c-Jun and PDGFb-RII, among genes upregulated by KLF4, and FGF-R2, Id2 and C/EBPd, among the repressed ones. The latter is particularly interesting, as it was placed upstream of p63 in the regulation of stem cells of the corneal limbus (Barbaro et al., 2007) , and targets of C/EBPd, such as Desmocollin 3 and other genes coding for desmosomal proteins (Smith et al., 2004) , are also targets of KLF4. Therefore, there seems to be an overlap in functions and it will now be important to establish the network of KLF4-regulated genes in the skin.
Forced expression of KLF4 in the basal layer of the skin has been experimentally tested in two transgenic mice models: inducible expression of KLF4 was driven by the Keratin 5 and Keratin 14 promoters, reaching somewhat different conclusions. One study showed that mouse skin undergoes decreased proliferation and anticipated differentiation, which is in line with the anti-growth, pro-differentiation aspect of KLF4 (Jaubert et al., 2003) . On the other hand, Foster et al. (2005) reported repeated cycles of hyperplasia and dysplasia in the skin, eventually leading to development of SCC in situ. The origin of the discrepancies between these studies is unclear; interestingly, however, the Foster et al. study also reported a genetic interaction with p53 in a p53 hemizygous mouse background. This is an important finding, as it established dysregulation of KLF4 as a predisposing factor for human skin cancer.
p53, p63 and KLF4 in skin cancer
The two most widespread non-melanoma cancers of epithelial origin in the skin are basal cell carcinomas (BCCs) and SCCs: the former is locally destructive, but it rarely metastasizes, while SCC cells have high metastatic potential (Tsai and Tsao, 2004) . The risk of developing SCC is directly related to UV exposure and susceptibility to sunburn. Mutations in p53 are widespread in SCC, clearly a predisposing factor, and indeed these tumors carry UVB 'signature' mutations. Importantly, patches of cells overexpressing mutant p53 proteins are detected in the interfollicular epidermis before skin tumors arise, and these 'p53 patches' are 
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N Cordani et al believed to be the precursors of SCCs (de Gruijl and Rebel, 2008) . The HaCaT cells analyzed here are immortalized and non-transformed KCs with mutant p53 allelles-R282Q and H179Y-and the levels of the p53 proteins are extremely high. They are not a model for skin cancer, as they are able to differentiate in vitro, unable to form colony assays in soft agar and do not generate tumors in nude mice in vivo (Boukamp et al., 1997; EM and RM, unpublished) . However, the p53 missense mutations harbored by HaCaT alleles are indeed UVB signature mutations (Pfeifer and Besaratinia, 2009 , and references therein). Two apparently contradictory results blur our vision as to the role of p53 in skin cancer: mice deficient for TP53 develop tumors resembling SCC after UV irradiation (Ziegler et al., 1994; Li et al., 1998; Jiang et al., 1999) , whereas Li-Fraumeni syndrome patients, who have a germline mutation in TP53, are not reported to be at increased risk for SCC (Malkin et al., 1990) . These findings should be put in the perspective of the growing body of evidence showing that p53 missense mutants not only lose normal p53 functions, but are also often pro-active in tumor formation (reviewed by Donzelli et al., 2008; Brosh and Rotter, 2009 ). Indeed, a set of gain-of-function mechanisms resulting from p53 mutations have been documented. Mutant p53 inactivation in HaCaT, overexpression in normal KC ChIPs and re-ChIPs clearly show that p53 mutations commonly found in SCC subvert the p63 negative regulation of KLF4, identifying a new pathway of co-regulation between p63 and mutant p53.
There are important mechanistic points that need to be addressed. The first is the interplay between p53 and p63/p73: although there is little evidence of heterotetrameric formation of p53-p63 dimers (Davison et al., 1999) , several reports have indicated that p63/p73 have an increased affinity for p53 missense mutants (Di Como et al., 1999; Strano et al., 2000; Gaiddon et al., 2001) . Specifically, p63 was reported to associate with the p53 mutants of HaCaT cells (Gaiddon et al., 2001) . The second is the finding that mutant p53 is associated with DNA in vivo in our ChIP assays. This is not the first report detecting binding of a potentially DNA-binding defective p53 mutant to DNA: binding could be tethered by NF-Y to CCAAT boxes in growth-promoting genes (Di Agostino et al., 2006) . This is not likely the case with the KLF4 promoter, which lacks any visible CCAAT box; rather, concomitant with the expression of the mutant p53 proteins, there is a relocation of p63 binding to the core promoter, in an area where canonical p53/p63 sites are present. Re-ChIP analysis is consistent with this. Finally, transient transfections with reporter assays devoid of upstream negative, but containing the positive core promoter sites, reproduced the positive effect of DNp63a on KLF4 transcription in HaCaT. Thus, we favor a scenario in which mutant p53 hijacks p63 from repressive to activating sites, either imparting novel DNA-binding or trans-activating features, or cooperating with additional neighboring TFs.
Interest in KLF4 has been recently spurred by the finding that it is one of the key TFs leading to reprogramming of differentiated cells into iPS (Takahashi and Yamanaka, 2006) . At the same time, high levels of KLF4 are found in SCC, which often have high levels of DNp63a (Deyoung and Ellisen, 2007) and mutant p53. A direct link between these three TFs is now established and this could have far-reaching effects in terms of our understanding of the genesis of skin tumors. In fact, the discovery that overexpression of a handful of TFs reprograms differentiated cells should generate a re-evaluation of the current hypothesis that tumors are derived from stem cells, as reprogramming of already partially differentiated cells, in the context of various genetic alterations, could also lead to tumor formation. UVB-derived p53 mutations confer gain-offunction properties to KCs, including direct targeting of a gene with reprogramming capacity, resulting in alteration of the growth-controlling capacity. The mechanistic details of the KLF4 role in normal KCs vs SCC will be understood once its targets are unveiled by genome-wide approaches.
Materials and methods
Cell culture and transfections
HaCaT cells and first passage primary human adult keratinocytes (haKCs), derived from healthy individuals (breast skin biopsies), were grown and handled as previously described (Vigano`et al., 2006) . Maintenance, differentiation and transfection of primary human neonatal keratinocytes (hnKCs; CellNtec, CH) were conducted as previously described (Pozzi et al., 2009) . For knockdown experiments, 50 nM siRNA oligonucleotides, with a scrambled sequence (Ambion, Foster City, CA, USA), or targeting the central DNA-binding domain of p63 or against p53 (5 0 -GACUCCAGUGGUAAUCUACTT-3 0 ), were used. For overexpression experiments, we used pcDNA3 vector, pcDNA3-DNp63a, pcDNA3-p53 wild type, pCR259-p53R282Q and pCR259-p53H179Y (Kato et al., 2003) . The KLF4 promoter-LUC was kindly provided by Vincent W Yang (Emory University, Atlanta, GA, USA).
Western blot analysis and antibodies Total or nuclear lysates were separated on 10% SDS-PAGE, transferred onto a nitrocellulose membrane, and probed using the following antibodies: 4A4 monoclonal anti-p63 (Santa Cruz, Santa Cruz, CA, USA), DO1 monoclonal anti-p53 (Genespin, I, Milan, Italy), polyclonal anti-KLF4 (Genespin, I) and monoclonal anti-Vinculin (Sigma, St Louis, MO, USA).
Immunofluorescence analysis
Immunofluorescence analysis of frozen human adult-thigh skin sections and cultured cells was performed as previously described (Vigano`et al., 2006) with anti-p63, anti-KLF4 (Genespin, I) and anti-KRT1 (Covance, Princeton, NJ, USA) antibodies. Nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI). Confocal images were obtained using a Leica TCS SP2 AOBS microscope (CIMAINA, University of Milano, Milano, Italy) with an Â 40 objective.
Chromatin immunoprecipitation
ChIP analysis was carried out as previously described , using the following antibodies: 4A4 monoclonal (Santa Cruz) and polyclonal anti-p63 (Genespin, I), DO1 monoclonal and polyclonal anti-p53 (Genespin), polyclonal anti-KLF4 (Santa Cruz; Genespin, I) and anti-Flag (Sigma). ChIP and re-ChIP experiments were performed as previously described (Furlan-Magaril et al., 2009 ) with DO1 monoclonal anti-p53 and polyclonal anti-p63 antibodies (Genespin, I). Location of potential p63/p53/KLF4 binding sites on the KLF4 promoter was performed by in silico analysis (Motif and ConSite; cutoff settings: 80-85%) applying single transcription factor specific criteria (Ortt and Sinha, 2006) . Primer pairs are listed in Supplementary 3. Fold enrichment for each TF was calculated as previously described (Pozzi et al., 2009 ).
Immunohistochemistry and skin tumor tissue arrays Paraffin sections of thickness 14 mm were deparaffinized and then blocked for 60 min in PBST (0.1% Triton X100 in PBS) with 2.5% donkey serum, 2.5% goat serum, 0.5% cold-water fish gelatin and 0.5% BSA. Primary antibodies were applied for 16 h at 4 1C and secondary antibodies were applied for 1 h at room temperature (RT). DAPI nuclei counterstaining was used. Tissue samples were fixed in buffered formalin, dehydrated, embedded in paraffin wax and sectioned. After deparaffinizing and rehydrating, each tissue section was immersed in citrate buffer, boiled 3 times for 5 min in a pressure cooker and washed with TBS buffer. Each section was placed on a Dako cytomation automated immunostainer and incubated with the specific antibody at RT for 45 min, washed with TBS pH 7.6 and incubated with biotinylated goat-antimouse-anti-rabbit immunoglobulins (Dako REAL, K5005, Dako, Dn) at RT for 30 min. After incubation with the secondary antibody and a new wash with TBS pH 7.6, sections were incubated with streptavidin conjugated to alkaline phosphatase at RT for 30 min A red chromogen solution was prepared as indicated by Dako REAL datasheet. Each section was counterstained in Mayer's hematoxylin solution and coverslipped.
Skin cancer tissue array (Z7020093, BioChain, Hayward, CA USA), including 48 cases in duplicates from surgical resection of normal, benign and cancerous tissue of the skin and subcutaneous tissues, were fixed in 10% neutral buffered formalin for 24 h and processed using identical SOPs. Sections were picked onto Superfrost Plus or Apes-coated Superfrost slides (Bio Optica, Milan, Italy).
